Programmatic Areas
In 2018, the Institute for Drug Discovery began forming multi-PI teams to establish and advance drug discovery projects.
The Institute for Drug Discovery has funded the following project teams:
| Lead PI | Co-Pi's | Project Description |
| Casey Krusemark | Mingji Dai, Markus Lill, Zhong-Yin Zhang | DNA-encoded, drug-like libraries based on privileged scaffolds generated by novel chemistry |
| Tony Hazbun | Mohamed Seleem, Dan Flaherty | Interdisciplinary program in antimicrobial drug discovery using repurposed small molecule drugs |
| Daisuke Kihara | Wen Jiang, Chang-Deng Hu | Deep neural network‐assisted protein structure modeling for drug development from low resolution 3D cryo‐electron microscopy maps |
| Richard van Rijn | Amy Brewster, Markus Lill, Dan Flaherty | β-arrestin 1 - a novel target for seizure disorders |
| Seung-Oe Lim | Michael Wendt, Zhong-Yin Zhang | A new strategy of immunotherapy by combining Src homology domain-containing phosphatase 2 inhibition and immune checkpoint blockade |
| Greg Hockerman |
Casey Krusemark, Yang Yang |
Discovery of subtype-selective ion channel inhibitors targeting extracellular toxin binding domains |
| Tiffany Lyle | Sophie Lelievre, Greg Knipp, Chris Rochet | Development of a novel BBB-on-a-chip model to improve selection of therapeutics |
| Bumsoo Han | Yoon Yeo, Tonglei Li, George Chiu | Program of precision pharmaceutics for precision medicines |
| Herman Sintim | Andy Mesecar, Gaurav Chopra, Greg Knipp, Bennett Elzey | New inhibitors against cancers harboring secondary kinase mutations |